Added to YB: 2026-09-14
Pitch date: 2026-09-10
TENX [neutral]
Tenax Therapeutics, Inc.
Author Info
No bio for this author
Company Info
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Market Cap
$122.0M
Pitch Price
N/A
Price Target
N/A
Dividend
N/A
EV/EBITDA
N/A
P/E
-1.45
EV/Sales
N/A
Sector
Biotechnology
Category
turnaround
Biotech Conference coverage, Day 2 Section 1 - Tenax Therapeutics, Inc.
TENX (watchlist): Tenax remains a high-risk watch after Phase 3 LEVEL missed statistical significance on its primary six-minute-walk endpoint. Management attributes the miss to healthier patients with limited room to improve; the lower-baseline-walk subgroup improved approximately 26–29 meters, and management also highlighted supportive biomarker and hemodynamic findings. LEVEL-2 must prospectively reproduce the subgroup effect, with regulatory acceptance of the enriched population and endpoint design still critical.
Read full article (1 min)